Clinical Trial Update: Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) [Phase 3]

View source ↗

Summary

Phase 3 trial update on irbesartan in heart failure with preserved systolic function (I-Preserve) completed; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• AVAPRO (irbesartan)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Congestive Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2010-06-08